MusclePharm(NYSE:R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, declared that Bodybuilding.com selected MusclePharm as the Supplement Company of the Month for October. Bodybuilding.com recognizes leading supplement companies with products and services that are making a positive impact on the industry and their consumers each month.
Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that developments and manufacturers a full line of NSF and scientifically approved, nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. MusclePharm's propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 US retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com.
Allos Therapeutics, Inc. (Nasdaq:ALTH) revealed the presentation of favorable survival data from Allos Therapeutics' international, randomized Phase 2b investigational study of FOLOTYN® (pralatrexate injection) relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population (n=201; hazard ratio (NYSE:HR)=0.84) and a 13 percent reduction in the risk of death in the primary efficacy analysis population (n=166; HR=0.87). At six months, 56 percent of patients treated with FOLOTYN were alive and 51 percent of patients treated with erlotinib were alive; at one year, 28 percent of patients treated with FOLOTYN were alive and 18 percent of patients treated with erlotinib were alive. The median overall survival (OS) time was 6.7 months for patients who received FOLOTYN and 7.0 months for patients who received erlotinib. The safety profile of FOLOTYN was consistent with that observed and reported in previous FOLOTYN solid tumor studies.
Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos Therapeutics is currently focused on the development and commercialization of FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors.
QLogic Corp. (NasdaqGS:QLGC) a leading supplier of high performance network infrastructure solutions reported recently preliminary results for its second quarter ended September 26, 2010. QLogic expects to report net revenue in the range of $146 million to $147 million for the second quarter of fiscal 2011, which represents a sequential increase of approximately 2 percent to 3 percent from the net revenue of $142.6 million for the first quarter of fiscal 2011. The updated expected net revenue is consistent with the high end of the previously forecasted second quarter net revenue range of $143 million to $147 million.
QLogic Corporation engages in the design and supply of storage networking, server networking, data networking, and converged networking infrastructure solutions. QLogic's products are used in server, workstation, and storage subsystem solutions that are used by small, medium, and large enterprises with business data requirements. QLogic sells its solutions to original equipment manufacturers and distributors worldwide. QLogic Corporation was founded in 1992 and is based in Aliso Viejo, California.
Focus Media Holding Ltd. (NasdaqGS:FMCN) China's leading digital media group, disclosed that Focus Media Holding have entered into a definitive agreement with Fosun International, one of their shareholders, pursuant to which Focus Media will repurchase from Fosun International 9,523,810 ADSs, each representing five ordinary shares of Focus Media Holding at a price of US$21 per ADS (or US$4.2 per ordinary share), totaling $200 million through a privately negotiated transaction.
Focus Media Holding Limited is China's leading multi-platform digital media company, operating the largest out-of-home advertising network in China using audiovisual digital displays, based on the number of locations and number of flat-panel television displays in our network. Through Focus Media Holding's multi-platform digital advertising network, Focus Media Holding reaches urban consumers at strategic locations and point-of-interests over a number of media formats, including audiovisual television displays in buildings and stores, advertising poster frames and other new and innovative media, such as outdoor light-emitting diode or LED digital billboard and Internet advertising platforms.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (OTCQB:MSLP).